NEW YORK – Despite careful planning and oversight, when a large health system in the Detroit area made the jump from rapid immunoassays to point-of-care molecular diagnostics using the Roche Cobas Liat platform for influenza testing, almost everything that could go wrong did.

Three flu seasons later, the health system is seeing benefits in terms of cost and patient management, but its initial experience is a cautionary tale for other lab managers considering the switch to molecular.